Benzoic acid (1R,3aR,4S,7aR)-7a-methyl-1-((S)-1-methyl-2-oxo-ethyl)-octahydro-inden-4-yl ester | 66774-71-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzoic acid (1R,3aR,4S,7aR)-7a-methyl-1-((S)-1-methyl-2-oxo-ethyl)-octahydro-inden-4-yl ester
• 英文别名: (8S,20S)-des-A,B-8-benzoyloxy-20-formylpregnane；des-A,B-8β-(benzoyloxy)-23,24-dinorcholane-22-al；(8S,20S)-des-A,B-8-benzoyloxy-20-formyl-pregnane；(8S,20S)-de-A,B-8-benzoyloxy-20-formylpregnane；de-A,B-8β-(benzoyloxy)-23,24-dinorcholan-22-al；(1R,3aR,4S,7aR)-7a-methyl-1-((S)-1-oxopropan-2-yl)octahydro-1H-inden-4-yl benzoate；[(1R,3aR,4S,7aR)-7a-methyl-1-[(2S)-1-oxopropan-2-yl]-1,2,3,3a,4,5,6,7-octahydroinden-4-yl] benzoate
• CAS: 66774-71-8
• 化学式: C₂₀H₂₆O₃
• 分子量: 314.425
• InChiKey: DCXYXPCMRLYABB-RDGCENLJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Benzoic acid (1R,3aR,4S,7aR)-7a-methyl-1-((S)-1-methyl-2-oxo-ethyl)-octahydro-inden-4-yl ester 在 bis-triphenylphosphine-palladium(II) chloride 喹啉 、 甲醇 、 4-二甲氨基吡啶 、 Lindlar's catalyst 、 2,6-二叔丁基吡啶 、 TMSTf 、 ion-exchange resin AG 50W-X₄ 、 氢气 、 四氯化钛 、 三乙胺 、 N,N-二异丙基乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 异辛烷 、 正己烷 、 二氯甲烷 为溶剂， 反应 80.67h， 生成 25-二羟基维生素D2
  参考文献：
  名称：

  Studies on the opening of dioxanone and acetal templates and application to the synthesis of 1.alpha.,25-dihydroxyvitamin D2

  摘要：

  The Lewis-acid-mediated nucleophilic substitution of dioxanone and acetal templates for the construction of 25-hydroxylated side chains of vitamin D2 metabolites and analogs has been studied. As an application a highly stereoselective synthesis of 1alpha,25-dihydroxyvitamin D2 by the dienyne route is described.

  DOI：

  10.1021/jo00053a024
• 作为产物：
  描述：

  (S)-2-((3R,3aR,7S,7aR)-octahydro-7-hydroxy-3a-methyl-1H-inden-3-yl)propyl 4-methylbenzenesulfonate 在 吡啶 、 2,4,6-三甲基吡啶 作用下， 以 二甲基亚砜 为溶剂， 反应 0.25h， 生成 Benzoic acid (1R,3aR,4S,7aR)-7a-methyl-1-((S)-1-methyl-2-oxo-ethyl)-octahydro-inden-4-yl ester
  参考文献：
  名称：

  Studies of vitamin D (calciferol) and its analogs. 43. Two novel allenic side chain analogs of 1.alpha.,25-dihydroxyvitamin D3

  摘要：

  Two new analogues of the steroid hormone 1-alpha,25-dihydroxyvitamin D3 (1) in which allenic functionality has been incorporated into the side chain have been synthesized. Both the 22S and 22R allene analogues (2a and 2b) were each separately synthesized in nine steps from a common precursor 9. While both analogues exhibited significant binding to the 1-alpha,25-dihydroxyvitamin D3 chick intestinal receptor, they showed low in vivo activity in stimulating intestinal calcium absorption in the chick.

  DOI：

  10.1021/jo00042a013

文献信息

• (22E)-2-METHYLENE-22-DEHYDRO-1ALPHA,24,25-TRIHYDROXY-19-NOR-VITAMIN D3 ANALOGS
  申请人：Wisconsin Alumni Research Foundation

  公开号：US20140206655A1

  公开（公告）日：2014-07-24

  Disclosed are (22E)-2-methylene-22-dehydro-1,24,25-trihydroxy-19-nor-vitamin D 3 compounds, their biological activities, and various pharmaceutical uses for these compounds. Particularly disclosed are (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D 3 and (22E)-(24S)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D 3 , their biological activities, and various pharmaceutical uses for these compounds.

  披露了(22E)-2-亚甲基-22-去氢-1,24,25-三羟基-19-去甲基维生素D3化合物，它们的生物活性以及这些化合物的各种药用。特别披露了(22E)-(24R)-2-亚甲基-22-去氢-1α,24,25-三羟基-19-去甲基维生素D3和(22E)-(24S)-2-亚甲基-22-去氢-1α,24,25-三羟基-19-去甲基维生素D3，它们的生物活性以及这些化合物的各种药用。
• [EN] PROCEDUCE FOR CRYSTALLIZATION OF (22E)-(24R)-2-METHYLENE-22-DEHYDRO-1A,24-25-TRIHYDROXY-19-NOR-VITAMIN D3<br/>[FR] PROCÉDÉ DE CRISTALLISATION DE (22E)-(24R)-2-MÉTHYLÈNE-22-DÉHYDRO-1A,24-25-TRIHYDROXY-19-NOR-VITAMINE D3
  申请人：WISCONSIN ALUMNI RES FOUND

  公开号：WO2019079279A1

  公开（公告）日：2019-04-25

  Disclosed are methods of purifying the compound (22E)-(247R)-2-methylene- 22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving (22E)-(24R)-2-methylene-22- dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 in a solvent comprising ethyl acetate and hexane to form a solution, allowing crystals of (22E)-(24R)-2-methylene-22-dehydro- 1α,24,25-trihydroxy-19-nor-vitamin D3 to form and precipitate from the solution, and recovering the crystals of (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor- vitamin D3 from the solution.

  揭示了一种纯化化合物(22E)-(24R)-2-甲烯基-22-脱氢-1α,24,25-三羟基-19-去甲维生素D3的方法，以获得晶体形式的化合物。这些方法通常包括以下步骤：将(22E)-(24R)-2-甲烯基-22-脱氢-1α,24,25-三羟基-19-去甲维生素D3溶解在包含乙酸乙酯和己烷的溶剂中形成溶液，使(22E)-(24R)-2-甲烯基-22-脱氢-1α,24,25-三羟基-19-去甲维生素D3的晶体形成并从溶液中沉淀出来，然后从溶液中回收(22E)-(24R)-2-甲烯基-22-脱氢-1α,24,25-三羟基-19-去甲维生素D3的晶体。
• Vitamin D analogs for obesity prevention and treatment
  申请人：DeLuca F. Hector

  公开号：US20050119242A1

  公开（公告）日：2005-06-02

  Methods for treating and preventing obesity, inhibiting adipocyte differentiation, inhibiting increased SCD-1 gene transcription, and/or reducing body fat in a subject include administering at least one analog of 1α,25-dihydroxyvitamin D 3 or 1α,25-dihydroxyvitamin D 2 or a pharmaceutical composition that includes such an analog to a subject in need thereof. The analog may be a 19-nor vitamin D analog such as a compound of formula IA, a compound of formula IB, or a mixture thereof where the variables R 1 , R 2 , and R 3 have the values described herein.

  治疗和预防肥胖的方法，抑制脂肪细胞分化，抑制增加的SCD-1基因转录，和/或减少受试者体脂肪的方法包括向需要的受试者施用至少一种1α,25-二羟基维生素D3或1α,25-二羟基维生素D2的类似物或包含这种类似物的药物组合物。该类似物可以是19-去甲基维生素D类似物，如式IA的化合物，式IB的化合物，或其中的混合物，其中变量R1、R2和R3具有此处描述的值。
• 2alpha-Methyl and 2beta-Methyl Analogs of 19,26-Dinor-1alpha,25-Dihydroxyvitamin D3 and Their Uses
  申请人：DeLuca Hector F.

  公开号：US20120283228A1

  公开（公告）日：2012-11-08

  This invention discloses 2α-methyl and 2β-methyl analogs of 19,26-dinor-1α,25-dihydroxyvitamin D 3 and pharmaceutical uses therefor. These compounds exhibit in vitro biological activities evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds have little, if any, in vivo calcemic activity and therefore may be used to treat autoimmune disorders in humans as well as secondary hyperparathyroidism and renal osteodystrophy.

  这项发明揭示了19,26-去甲基-1α,25-二羟基维生素D3的2α-甲基和2β-甲基类似物以及其药用。这些化合物在体外表现出生物活性，可作为抗癌剂以及治疗银屑病等皮肤疾病，以及皱纹、松弛皮肤、干燥皮肤和皮脂分泌不足等皮肤状况的用途。这些化合物在体内几乎没有钙调节活性，因此可用于治疗人类的自身免疫性疾病，以及继发性甲状旁腺功能亢进和肾性骨病。
• 2-Methylene-(20S,25S)-19,26-Dinor-Vitamin D Analogs
  申请人：DeLuca Hector F.

  公开号：US20090170821A1

  公开（公告）日：2009-07-02

  This invention discloses 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,26-dinor-1α,25-dihydroxyvitamin D 3 , and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

  这项发明披露了2-亚甲基-(20S,25S)-19,26-二诺尔维生素D类似物，具体为2-亚甲基-(20S,25S)-19,26-二诺尔-1α,25-二羟基维生素D3，以及其药用。该化合物在阻止未分化细胞增殖和诱导它们向单核细胞分化方面表现出显著活性，因此可作为抗癌剂以及用于治疗银屑病等皮肤疾病以及皱纹、松弛皮肤、干燥皮肤和皮脂分泌不足等皮肤状况的药物。该化合物在钙代谢方面几乎没有活性，因此可用于治疗人类的自身免疫性疾病或炎症性疾病，以及肾性骨病。此外，该化合物还可用于肥胖的治疗或预防。